Change in basal ganglia volume over 2 years in patients with schizophrenia: Typical versus atypical neuroleptics

American Journal of Psychiatry

Volumn 156, Issue 8, 1999, Pages 1200-1204

  Westmoreland Corson, Patricia ^a   Nopoulos, Peg ^b   Miller, Del D ^b   Arndt, Stephan ^b   Andreasen, Nancy C ^b  

^a UNIVERSITY OF IOWA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; ARTICLE; BASAL GANGLION; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; DRUG EFFECT; DRUG EXPOSURE; DRUG RESPONSE; FOLLOW UP; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; CAUDATE NUCLEUS; CORPUS STRIATUM; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PUTAMEN; SCHIZOPHRENIA;

EID: 0344500596     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Heckers S, Heinsen H, Heinsen Y, Beckmann H: Cortex, white matter and basal ganglia in schizophrenia: a volumetric postmortem study. Biol Psychiatry 1991; 29:556-566
2. Gur RE, Pearison GD: Neuroimaging in schizophrenia research. Schizophr Bull 1993; 19:337-353
3. De Lisi LE, Hoff AL, Tew W, Sakuma M, Crimson R: Brain structure change over time in first episode schizophrenia (abstract). Schizophr Res 1997; 24:141-142
4. Jernigan TL, Zisook S, Heaton RK, Moranville JT, Hesselink JR, Braff DL: Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia. Arch Gen Psychiatry 1991; 48:881-890
5. Breier A, Buchanan RW, Elkashef A, Munson RC, Kirkpatrick B, Gellad F: Brain morphology in schizophrenia: a magnetic resonance imaging study of limbic, prefrontal cortex and caudate structures. Arch Gen Psychiatry 1992; 49:921-926
6. Swayze VW II, Andreasen NC, Alliger RJ, Yuh WT, Ehrhardt JC: Subcortical and temporal structures in affective disorder and schizophrenia: a magnetic resonance imaging study. Biol Psychiatry 1992; 31:221-240
7. Nasrallah HA, Chu O, Olsen SC, Martin R: Increased caudate volume in schizophrenia: a controlled MRI study (abstract). Schizophr Res 1993; 9:204
8. Elkashef AM, Buchanan RW, Gellad F, Munson RC, Breier A: Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. Am J Psychiatry 1994; 151: 752-755
9. Frazier JA, Gied JN, Kaysen D, Albus K, Hamburger S, Alaghband-Rad J, Lenane MC, McKenna K, Breier A, Rapoport JL: Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. Am J Psychiatry 1996;153:564-566
10. Chakos MH, Lieberman JA, Bilder RM, Borenstein M, Lerner G, Bogerts B, Wu H, Kinon B, Ashtari M: Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994; 151:1430-1436
11. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler N, Pettegrew JW: Changes in caudate volume with neuroleptic treatment (letter). Lancet 1994; 344:1434
12. Rodriguez R, Flaum M, Nopoulos P: The effect of cumulative neuroleptic exposure on caudate and putamen volume (abstract). Schizophr Res 1997; 24:154-155
13. Doraiswamy PM, Tupler LA, Krishnan KRR: Neuroleptic treatment and caudate plasticity (letter). Lancet 1995; 345:734-735
14. Miller DD, Rezai K, Alliger R, Andreasen NC: The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: assessment with technetium-99m hexamethylpropyleneamine oxime single photon emission computed tomography. Biol Psychiatry 1997; 41:550-559
15. Miller DD, Andreasen NC, O'Leary DS, Rezai K, Watkins GL, Ponto LL, Hichwa RD: Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography. Neuropsychopharmacology 1997; 17:230-240; correction, 1998; 18:323-324
16. Chakos MH, Lieberman JA, Alvir J, Bilder R, Ashtari M: Caudate nuclei volumes in patients treated with typical antipsychotics or clozapine (letter). Lancet 1995; 345:456-457
17. Miller DD, Flaum MA, Nopoulos P, Arndt S, Andreasen NC: The concept of dose years: a reliable method for calculating lifetime psychotropic drug exposure (abstract). Schizophr Res 1995; 15:159
18. Andreasen NC, Flaum M, Arndt S: The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992; 49:615-623
19. Davis JM: Dose equivalence of the antipsychotic drugs. J Psychiatry Res 1974; 11:65-69
20. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997; 154(April suppl)
21. Andreasen NC, Cohen G, Harris G, Cizadlo T, Parkkinen J, Rezai K, Swayze VW II: Image processing for the study of brain structure and function: problems and programs. J Neuropsychiatry Clin Neurosci 1992; 4:125-133
22. Graybiel AM: The basal ganglia and cognitive pattern generators. Schizophr Bull 1997; 23:459-469
23. Arnt J, Skarsfeldt T, Hyttel J: Differentiation of classical and novel antipsychotics using animal models. Int Clin Psychopharmacol 1997; 12(suppl 1):S9-S17
24. Pehek EA, Yamamoto BK: Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J Neurochem 1994;63:2118-2124
25. Sedvall G, Pauli S, Farde L, Karlsson P, Nyberg S, Nordstrom A-L: Recent developments in PET scan imaging of neuroreceptors in schizophrenia. Isr J Psychiatry Relat Sci 1995; 32: 22-29
26. Pilowsky LS, Mulligan RS, Acton PD, EII P, Costa DC, Kerwin RW: Limbic selectivity of clozapine. Lancet 1997; 350:490-491
27. 123I IBZM single proton emission tomography (SPET) study. Psychopharmacology (Berl) 1996; 124:148-153
28. Clardy JA, Hyde TM, Kleinman JE: Postmortem neurochemical and neuropathological studies in schizophrenia, in Schizophrenia: From Mind to Molecule. Edited by Andreasen NC. Washington, DC, American Psychiatric Press, 1994, pp 123-145
29. Clow A, Theodorou A, Jenner P, Marsden CD: A comparison of striatal and mesolimbic dopamine function in the rat during 6-month trifluoperazine administration. Psychopharmacology (Berl) 1980; 69:227-233
30. Seeman P, Bzowej NH, Guan HC: Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases. Neuropsychopharmacology 1987;1:5-15
31. Joyce JN, Lexow N, Bird E: Organization of dopamine D1 and D2 receptors in the human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 1988; 2:546-557
32. Hokama H, Shenton ME, Nestor PG, Kikinis R, Levitt JJ, Metcalf D, Wible C, O'Donnell B, Jolesz FA, McCarley RW: Caudate, putamen and globus pallidus volume in schizophrenia: a quantitative MRI study. Psychiatry Res Neuroimaging 1995; 61:209-229